The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 9, 2022

Study Completion Date

September 9, 2022

Conditions
Acute Lung Injury
Interventions
DRUG

Aspirin 75mg

Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.

DRUG

Lactose powder

Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.

DRUG

Aspirin 1200mg

Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.

Trial Locations (1)

Unknown

Belfast Health and Social Care Trust, Belfast

Sponsors
All Listed Sponsors
collaborator

The Intensive Care Society United Kingdom

UNKNOWN

collaborator

Northern Ireland Clinical Trials Unit

OTHER

collaborator

Queen's University, Belfast

OTHER

lead

Belfast Health and Social Care Trust

OTHER

NCT01659307 - The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury | Biotech Hunter | Biotech Hunter